Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway

Figure 6

Effects of pulsed zoledronic acid on follistatin secretion from ER-ve cell lines. The difference in follistatin secretion according to ER status is not due to differences in cellular uptake of the drug. A. MDA-MB-231 and MDA-MB-436 cells were treated for 4 hours with 50 μM of ZOL followed by a 44 hour incubation with medium alone or medium alone for 48 hours (CON). Follistatin levels in the supernatant was removed and processed for ELISA. Data represents mean + SEM of 3 replicates and 3 repeats, **= p value <0.01, ***= p value <0.001. B. MDA-MB-231 and MCF7 cells were treated for 48 hours with medium alone (C), GGOH 50 μM (G), Zol 10 μM (Z) or both G and Z in combination (ZG). Rap1a antibody (1:200) used to assess levels of unprelylated protein and GAPDH (1:20,000) used as loading control.

Back to article page